Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Rethinking thresholds in ER-Low TNBC for future studies

Francois Cherifi • 15 Oct 2024
ESMO 2024
Breast Cancer

Francois Cherifi, MD, CLCC Francois Baclesse, Caen, France, addresses the need for flexibility in defining ER-low thresholds for triple-negative breast cancer (TNBC) in future studies. Current cutoff points are seen as restrictive and a more nuanced approach that incorporates broader biological features, rather than solely relying on receptor expression, is suggested. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francois Cherifi

Insights from the PROMENADE study on ER-low triple-negative breast cancer
0:30
Insights from the PROMENADE study on ER-low triple-negative breast cancer
Francois Cherifi • 15 Sep 2024
Reevaluating treatment approaches for ER-Low TNBC
0:47
Reevaluating treatment approaches for ER-Low TNBC
Francois Cherifi • 15 Sep 2024
PROMENADE: highlighting TNBC in younger patients with aggressive features
1:03
PROMENADE: highlighting TNBC in younger patients with aggressive features
Francois Cherifi • 15 Sep 2024
Real-world insights on pembrolizumab for ER-low triple-negative breast cancer
2:46
Real-world insights on pembrolizumab for ER-low triple-negative breast cancer
Francois Cherifi • 15 Sep 2024

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals